Patent classifications
A61K31/4406
Histone deacetylase inhibitors for immunomodulation in tumor microenvironment
The present disclosure generally relates to compounds class I HDAC inhibitors, their production and applications. The compounds possess epigenetic immunomodulatory activities in the tumor microenvironment (TME) and thus inhibit growth of tumor cells.
Histone deacetylase inhibitors for immunomodulation in tumor microenvironment
The present disclosure generally relates to compounds class I HDAC inhibitors, their production and applications. The compounds possess epigenetic immunomodulatory activities in the tumor microenvironment (TME) and thus inhibit growth of tumor cells.
COMPOUNDS FOR USE IN THE REACTIVATION OF HIV IN LATENT HIV-INFECTED CELLS
The present invention relates to compounds capable of binding to the Tat-TAR complex in latent HIV-infected cells, so as to transactivate the Tat protein and promote the lifting of HIV latency in said cells.
Method of vaccination comprising a histone deacetylase inhibitor
A vaccination method is provided. The method comprises administering to a mammal a histone deacytelase inhibitor in conjunction with a vaccine that expresses an antigen to which the mammal has a pre-existing immunity.
Method of vaccination comprising a histone deacetylase inhibitor
A vaccination method is provided. The method comprises administering to a mammal a histone deacytelase inhibitor in conjunction with a vaccine that expresses an antigen to which the mammal has a pre-existing immunity.
Method of vaccination comprising a histone deacetylase inhibitor
A vaccination method is provided. The method comprises administering to a mammal a histone deacytelase inhibitor in conjunction with a vaccine that expresses an antigen to which the mammal has a pre-existing immunity.
COMBINATION THERAPIES OF HDAC INHIBITORS AND PD-L1 INHIBITORS
Provided herein are combinations that include an HDACi and a PD-L1 inhibitor that are useful for treating cancer, including cancer resistant to PD-1 inhibitors.
COMBINATION THERAPIES OF HDAC INHIBITORS AND PD-L1 INHIBITORS
Provided herein are combinations that include an HDACi and a PD-L1 inhibitor that are useful for treating cancer, including cancer resistant to PD-1 inhibitors.
COMBINATION THERAPIES OF HDAC INHIBITORS AND PD-L1 INHIBITORS
Provided herein are combinations that include an HDACi and a PD-L1 inhibitor that are useful for treating cancer, including cancer resistant to PD-1 inhibitors.
COMBINATION THERAPIES OF HDAC INHIBITORS AND PD-1 INHIBITORS
Provided herein are combinations that include an HDACi and a PD-1 inhibitor that are useful for treating cancer, including reducing and/or preventing cancer metastasis. The combination is also useful for treating cancer that has been previously treated with a PD-L1 inhibitor.